Annovis Bio Inc. (NYSE: ANVS) has priced an underwritten public offering expected to generate approximately $15 million in gross proceeds, the company announced. The offering consists of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares, sold at a combined price of $1.90 per share and warrant. Net proceeds will support continued clinical development of buntanetap, the company's lead drug candidate for Alzheimer’s disease (AD) and Parkinson’s disease (PD), as well as working capital and general corporate purposes.
The announcement comes as Annovis Bio, a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, seeks to advance treatments for neurodegenerative diseases. Buntanetap (formerly posiphen) is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
This capital raise is significant for the company as it funds pivotal trials for buntanetap, which could potentially address a large unmet need in Alzheimer’s and Parkinson’s diseases. According to the Alzheimer’s Association, more than 6 million Americans live with Alzheimer’s, and the Parkinson’s Foundation estimates nearly 1 million in the U.S. have Parkinson’s. Current treatments primarily manage symptoms rather than slow or stop disease progression.
The offering underscores Annovis Bio’s commitment to advancing its pipeline despite the challenging biotechnology funding environment. The company’s stock, listed on the NYSE under the ticker ANVS, may experience volatility as investors assess the dilutive impact of the offering against the potential of buntanetap. Full details of the offering are available in the press release on the company’s newsroom at https://ibn.fm/ANVS.
Investors and stakeholders will be watching for upcoming clinical data readouts, which could provide further insight into buntanetap’s efficacy and safety profile. The success of these trials is critical for Annovis Bio’s trajectory, as positive results could position the company as a key player in the neurodegenerative disease treatment landscape.
